Affimed (NASDAQ:AFMD) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lowered its holdings in Affimed (NASDAQ:AFMDGet Rating) by 48.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 233,266 shares of the biopharmaceutical company’s stock after selling 215,073 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.19% of Affimed worth $1,019,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Chartwell Investment Partners LLC increased its position in shares of Affimed by 4.4% in the first quarter. Chartwell Investment Partners LLC now owns 69,684 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 2,918 shares in the last quarter. Virtus ETF Advisers LLC increased its position in Affimed by 20.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 30,588 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 5,166 shares in the last quarter. Bank of New York Mellon Corp increased its position in Affimed by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company’s stock worth $1,323,000 after purchasing an additional 5,513 shares in the last quarter. Advisor Group Holdings Inc. increased its position in Affimed by 258.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 6,464 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its position in Affimed by 34.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 41,854 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 10,695 shares in the last quarter. Institutional investors and hedge funds own 71.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. SVB Leerink dropped their price objective on Affimed from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Thursday, June 23rd. StockNews.com raised Affimed from a “sell” rating to a “hold” rating in a research note on Monday, August 22nd. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of Affimed in a research note on Thursday, August 18th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Affimed Stock Performance

Affimed stock opened at $2.62 on Friday. The stock’s 50 day moving average price is $2.97 and its 200 day moving average price is $3.51. The firm has a market capitalization of $323.36 million, a PE ratio of -3.80 and a beta of 2.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.89 and a current ratio of 4.90. Affimed has a one year low of $2.23 and a one year high of $7.35.

Affimed (NASDAQ:AFMDGet Rating) last released its quarterly earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $7.78 million for the quarter, compared to analyst estimates of $8.12 million. Affimed had a negative return on equity of 54.94% and a negative net margin of 232.11%. As a group, sell-side analysts expect that Affimed will post -0.67 EPS for the current fiscal year.

About Affimed

(Get Rating)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.

Read More

Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed (NASDAQ:AFMDGet Rating).

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.